EDAP TMS S.A. Confirms Strong Clinical Leadership on HIFU for the Treatment of Localized Prostate Cancer
24 Febrero 2005 - 7:10AM
PR Newswire (US)
EDAP TMS S.A. Confirms Strong Clinical Leadership on HIFU for the
Treatment of Localized Prostate Cancer More Than 6,600 Ablatherm
Treatments Procedures Performed to date Successful Results at 8
Years to be Presented at the Next European Urology Congress LYON,
France, Feb. 24 /PRNewswire-FirstCall/ -- EDAP TMS S.A.
(NASDAQ:EDAP), today confirms its strong clinical leadership on
HIFU technology using Ablatherm(R). EDAP continues to validate its
clinical leadership position and credibility in the High Intensity
Focused Ultrasound (HIFU) treatment of localized prostate cancer
with more than 6,600 Ablatherm treatments performed to date. HIFU
is now widely recognized within the medical community as a solution
for patients who are not candidates for surgery or who failed
radiotherapy treatment. In 2004, more than 20 abstracts referring
to the use of HIFU with Ablatherm were presented by Urologists
using Ablatherm at various international congresses. Three articles
were published in peer reviewed urological journals. For more
information, please feel free to visit our web site dedicated to
HIFU with Ablatherm http://www.edap-hifu.com/. EDAP continues to
build its Ablatherm business and expand its market share while
benefiting from the support of key opinion leaders and urologists.
In line with the strategy to educate both patients and physicians
regarding HIFU with Ablatherm as a successful therapeutic option
for patients suffering from prostate cancer, EDAP will be actively
participating in the next European Association of Urology (EAU)
meeting in Istanbul, Turkey, March 16-19, 2005 (Booth C17). Dr. S.
Thuroff, from Harlaching Hospital, Munich, Germany, will be
presenting successful clinical results at eight years following
Ablatherm treatment. Dr. J. Lunz from Caritas Krankenhaus St Joseph
Hospital, Regensburg, Germany, will address the better quality of
life obtained following Ablatherm treatment compared to radical
surgery. Dr. A. Gelet from Edouard Herriot Hospital, Lyon, France,
will present updated results obtained after the use of HIFU with
Ablatherm on patients who failed radiotherapy treatment. Three
additional abstracts referring to the use of Ablatherm will also be
discussed over the course of this conference. Hugues de Bantel,
Chief Executive Officer of EDAP TMS, commented: "We are very
pleased with the number of HIFU with Ablatherm treatments completed
as of the end of 2004. The increasing growth rates in Ablatherm
treatment clearly confirm our position as the leading provider in
the field of HIFU treatment for prostate cancer. With more than
230,000 new prostate cancer cases diagnosed every year in the
United States and more than 250,000 new cases in Europe, our market
scope is tremendous. We are positioning EDAP for rapid expansion
and market share growth. EDAP's strategy will include the
continuing education of both patients and physicians regarding HIFU
with Ablatherm treatment options, as well as developing our mobile
business by offering a payment per procedure performed model, to
doctors and hospitals. We are also enthusiastic about our results
obtained on patients who failed radiotherapy treatment. With more
than 300 treatments performed to date, HIFU with Ablatherm offers a
unique curative option to patients who are facing a therapeutic
dead end. EDAP is presently working to offer this solution to a
wider range of patients facing similar failures from prior
treatment." About EDAP TMS S.A. EDAP TMS S.A. develops and markets
Ablatherm, the most advanced and clinically proven choice for High
Intensity Focused Ultrasound (HIFU) treatment of localized prostate
cancer. HIFU treatment is shown to be a minimally invasive and
effective treatment option with a low occurrence of side effects.
The company is also developing this technology for the treatment of
certain other types of tumors. EDAP TMS S.A. also produces and
commercializes medical equipment for treatment of urinary tract
stones using Extra-corporeal Shockwave Lithotripsy (ESWL). For more
information on the Company, contact the Investor Relations Dept by
phone at +33 (0)4 78 26 40 46 or see the Company's Web site at:
http://www.edap-tms.com/. This press release contains, in addition
to historical information, forward-looking statements that involve
risks and uncertainties. These include statements regarding the
Company's growth and expansion plans. Such statements are based on
management's current expectations and are subject to a number of
uncertainties and risks that could cause actual results to differ
materially from those described in the forward-looking statements.
Factors that may cause such a difference include, but are not
limited to, those described in the Company's filings with the
Securities and Exchange Commission. DATASOURCE: EDAP TMS S.A.
CONTACT: Hugues de Bantel, Philippe Chauveau, or Blandine Confort,
all of EDAP TMS S.A., +33-4-78-26-40-46; or Matt Kreps or Geralyn
DeBusk, both of Halliburton Investor Relations, +1-972-458-8000,
for EDAP TMS S.A. Web site: http://www.edap-tms.com/
http://www.edap-hifu.com/
Copyright
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
EDAP TMS (NASDAQ:EDAP)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024